ResearcherTsinghua UniversityNo recent work listed
Huiqin Liu
Matched on ORCID iD 0000-0002-5754-2623; OpenAlex author ID A5016019821. Sources: OpenAlex.
Their work
- Papers
- 7 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 8
2019: 2 papers · 2020: none · 2021: 1 paper · 2022: 4 papers
Papers 7
- Synergistic autophagy blockade and VDR signaling activation enhance stellate cell reprogramming in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2022.215718↗
- Albumin binding revitalizes NQO1 bioactivatable drugs as novel therapeutics for pancreatic cancer. First author DOI 10.1016/j.jconrel.2022.07.033↗
- Corrigendum to "Albumin binding revitalizes NQO1 bioactivatable drugs as novel therapeutics for pancreatic cancer" [Journal of Controlled Release 349 (2022) 87… First author DOI 10.1016/j.jconrel.2022.08.013↗
- Macropinocytic dextran facilitates KRAS-targeted delivery while reducing drug-induced tumor immunity depletion in pancreatic cancer. Co-author DOI 10.7150/thno.65299↗
- Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts. Co-author DOI 10.1016/j.addr.2021.02.012↗
- KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs. Co-author DOI 10.1016/j.jconrel.2019.01.014↗
- Targeting the Oncogene KRAS Mutant Pancreatic Cancer by Synergistic Blocking of Lysosomal Acidification and Rapid Drug Release. Co-author DOI 10.1021/acsnano.8b08246↗
Closest collaborators
The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Feng Qian · 6 shared papers, 2019–2022 · strength 0.90
- Paper Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts. DOI 10.1016/j.addr.2021.02.012↗
- Paper Macropinocytic dextran facilitates KRAS-targeted delivery while reducing drug-induced tumor immunity depletion in pancr… DOI 10.7150/thno.65299↗
- Paper Synergistic autophagy blockade and VDR signaling activation enhance stellate cell reprogramming in pancreatic ductal ad… DOI 10.1016/j.canlet.2022.215718↗
- Weijian Kong · 4 shared papers, 2019–2022 · strength 0.52
- Paper Macropinocytic dextran facilitates KRAS-targeted delivery while reducing drug-induced tumor immunity depletion in pancr… DOI 10.7150/thno.65299↗
- Paper Synergistic autophagy blockade and VDR signaling activation enhance stellate cell reprogramming in pancreatic ductal ad… DOI 10.1016/j.canlet.2022.215718↗
- Paper KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated dr… DOI 10.1016/j.jconrel.2019.01.014↗
- Chao Kong · 3 shared papers, 2019–2022 · strength 0.35
- Paper Synergistic autophagy blockade and VDR signaling activation enhance stellate cell reprogramming in pancreatic ductal ad… DOI 10.1016/j.canlet.2022.215718↗
- Paper KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated dr… DOI 10.1016/j.jconrel.2019.01.014↗
- Paper Targeting the Oncogene KRAS Mutant Pancreatic Cancer by Synergistic Blocking of Lysosomal Acidification and Rapid Drug … DOI 10.1021/acsnano.8b08246↗
- Lei Dou · 2 shared papers, 2022 · strength 0.31
- Paper Albumin binding revitalizes NQO1 bioactivatable drugs as novel therapeutics for pancreatic cancer. DOI 10.1016/j.jconrel.2022.07.033↗
- Paper Corrigendum to "Albumin binding revitalizes NQO1 bioactivatable drugs as novel therapeutics for pancreatic cancer" [Jou… DOI 10.1016/j.jconrel.2022.08.013↗
- Yu Shi · 1 shared paper, 2021 · strength 0.22
- Yuan Fang · 1 shared paper, 2022 · strength 0.17
- Rui Wang · 1 shared paper, 2022 · strength 0.16
- Qian Feng · 1 shared paper, 2022 · strength 0.16
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.